TY - JOUR T1 - Treatment of CIDP JF - Practical Neurology JO - Pract Neurol DO - 10.1136/pn-2021-002991 SP - pn-2021-002991 AU - Janev Fehmi AU - Roberto Bellanti AU - Siraj A Misbah AU - Anupam Bhattacharjee AU - Simon Rinaldi Y1 - 2022/09/15 UR - http://pn.bmj.com/content/early/2022/09/14/pn-2021-002991.abstract N2 - Chronic inflammatory demyelinating polyneuropathy is a disabling but treatable disorder. However, misdiagnosis is common, and it can be difficult to optimise its treatment. Various agents are used both for first and second line. First-line options are intravenous immunoglobulin, corticosteroids and plasma exchange. Second-line therapies may be introduced as steroid-sparing agents or as more potent escalation therapy. It is also important to consider symptomatic treatment of neuropathic pain and non-pharmacological interventions. We discuss the evidence for the various treatments and explain the practicalities of the different approaches. We also outline strategies for monitoring response and assessing the ongoing need for therapy.All data relevant to the study are included in the article. ER -